<DOC>
	<DOCNO>NCT00000710</DOCNO>
	<brief_summary>To determine safety , pharmacokinetics ( blood level ) , effectiveness didanosine ( ddI ) administer intravenously orally . After maximum tolerate dose ( MTD ) determine , appropriate dosage regimen establish Phase II Phase III trial . Zidovudine ( AZT ) produce best clinical result drug therapy AIDS date , produce toxicity approximately 50 percent patient . Early data show ddI possess high antiviral activity less toxicity AZT . The effective route dose ddI yet determine .</brief_summary>
	<brief_title>A Phase I Safety , Efficacy , Pharmacokinetic Study 2',3'-Dideoxyinosine ( ddI ) Administered Twice Daily Patients With AIDS AIDS Related Complex</brief_title>
	<detailed_description>Zidovudine ( AZT ) produce best clinical result drug therapy AIDS date , produce toxicity approximately 50 percent patient . Early data show ddI possess high antiviral activity less toxicity AZT . The effective route dose ddI yet determine . Patients give intravenous drug 14 day 1 day washout period , 76 week oral medication . To expedite safety study still able maintain close monitoring patient 's health , overlap dose regimen use . After 6 patient enrol least 4 complete 4 week dose without significant toxic effect , second group patient start next dose level . AMENDED : An alternative oral dose formulation ddI provide buffer powder blend package seal foil sachet several strength .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>AIDS-Related Complex</mesh_term>
	<mesh_term>Didanosine</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Recommended : Allopurinol consistent occurrence hyperuricemia observe 2',3'dideoxyinosine ( ddI ) administration . Allowed : Aerosolized pentamidine Pneumocystis carinii pneumonia ( PCP ) prophylaxis . Oral acyclovir herpes simplex infection provide ddI dose suspended time . Ketoconazole patient respond therapy consultation sponsor . Symptomatic therapy analgesic , antihistamine , antiemetic , antidiarrheal agent , supportive therapy may administer deem necessary principal investigator . Aspirin rather acetaminophen fever . Patients follow include : An absence lifethreatening opportunistic infection enrollment . A life expectancy le 6 month . Available followup least 6 month . Able provide inform consent . Exclusion Criteria Coexisting Condition : Patients follow exclude : Intractable diarrhea . No venous access . A history propensity seizure disorder . A history past current heart disease significant abnormality routine EKG . Concurrent Medication : Excluded : Adenine deaminase inhibitor . Trimethoprim / sulfamethoxazole Pneumocystis carinii pneumonia ( PCP ) infection . Antibiotics . Acetaminophen therapy fever . Patients follow exclude : Intractable diarrhea . A life expectancy le 6 month . No venous access . A history propensity seizure disorder . A history past current heart disease significant abnormality routine EKG . Prior Medication : Excluded : Any agent know potent inducer inhibitor drugmetabolizing enzyme . Excluded within 2 week study entry : Trimethoprim / sulfamethoxazole . Excluded within 1 month study entry : Any antiretroviral drug . Investigational agent . 2',3'didanosine . AL721 . Interferons . Immunomodulating drug . Excluded within 3 month study entry : Ribavirin . Cytotoxic agent . Risk Behavior : Excluded : Active alcohol drug abuse sufficient investigator 's opinion prevent adequate compliance .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Injections , Intravenous</keyword>
	<keyword>Didanosine</keyword>
	<keyword>Dose-Response Relationship , Drug</keyword>
	<keyword>Drug Evaluation</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>AIDS-Related Complex</keyword>
</DOC>